A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

NCT07275840 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: IBI302 8mg dose

Sponsor

Innovent Biologics Technology Limited (Shanghai R&D Center)